Back to search

Article

In vitro activity of cefiderocol against Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis

2025-08-26

Abstract excerpt

<h4>Background: </h4> Pseudomonas aeruginosa is a key pathogen in cystic fibrosis (CF), driving pulmonary decline and exhibiting resistance through virulence factors and adaptive mutations. Cefiderocol (FDC) is a novel siderophore cephalosporin with activity against Gram-negative bacteria. We aimed to assess the in vitro efficacy of FDC against P. aeruginosa isolates in a CF population.     Methods The study was c...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
21a41e18-f6c4-5af9-ae80-a94db7418c7a
DOI
10.1099/acmi.0.001001.v2
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
In vitro activity of cefiderocol against Pseudomonas aeruginosa isolated from adult patients with cystic fibrosisDOI 10.1099/acmi.0.001001.v2
In vitro activity of cefiderocol against Pseudomonas aeruginosa isolated from adult patients with cystic fibrosisSemantic proximity
In vitro activity of cefiderocol in Pseudomonas aeruginosa isolates from people with cystic fibrosis recovered during three multicentre studies in Spain.Semantic proximity
Activity of cefiderocol against Pseudomonas aeruginosa from the USA and Europe (2020-2023) with difficult-to-treat resistance phenotype, including those nonsusceptible to recently developed β-lactam/β-lactamase inhibitor combinations: results from the SENTRY antimicrobial surveillance program.Semantic proximity
In Vitro Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019Semantic proximity
Mechanisms involved in cefiderocol resistance in French <i>Pseudomonas aeruginosa</i> clinical strainsSemantic proximity
In Vitro Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance ProgramSemantic proximity
In vitro activity assessment of cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp., including β-lactam nonsusceptible molecularly characterized isolates, collected from 2020 to 2021 in the United States and European hospitalsSemantic proximity
An Overview of Cefiderocol’s Therapeutic Potential and Underlying Resistance MechanismsSemantic proximity
Real-world multicentre study of cefiderocol treatment of immunocompromised patients with infections caused by multidrug-resistant Gram-negative bacteria: CEFI-IDSemantic proximity
AtbFinder Diagnostic Test System Improves Optimal Selection of Antibiotic Therapy in Persons with Cystic FibrosisSemantic proximity
In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014–2019)Semantic proximity
Emergence of cefiderocol resistance mediated by blaAFM-1 overexpression and FptA mutations in clinical carbapenem-resistant Pseudomonas aeruginosa isolates.Semantic proximity
Select a neighboring publication to make it the new centre.